We hypothesize that the presence of ER+ RANK-positive cells within a tumor, with higher ER expression and sustained NF-kB pathway activity, may represent an important reservoir of HT-resistant cells, which may have the skills to survive therapies that kill HT-sensitive tumor cells. This evidence concerns the gene TNFRSF11A and neoplasm.